Cancer Research UK and partners have committed \u00a35.5 million in funding to form a world-leading research team, co-led by NDM\u2019s Professor Simon Leedham. The team\u2019s goal is to make personalised medicine a reality for people with bowel cancer.
The Jenner Institute, in partnership with the Coler Lab at Seattle Children\u2019s Research Institute (SCRI), is set to begin a new clinical trial to test tuberculosis (TB) vaccine safety and the host immune response in a first-in-man aerosol mycobacterial challenge infection model with healthy adult volunteers.
Thanks to cutting edge research at NDM's Jenner Institute and Oxford University Clinical Research Unit (OUCRU), Oxford remains at the forefront of research to develop new vaccines to protect against this devastating disease.
In a recent study, researchers at the KEMRI Wellcome Trust Research Programme in Kenya have discovered that a low-dose of the yellow fever vaccine is as effective as the current standard dose.
Scientists have found another clue about how brain health is maintained and how this might be affected by ageing and Alzheimer\u2019s disease, according to a new paper.
Researchers have published the first paper mapping clinical ethics questions raised by new metagenomic techniques for diagnosing disease in clinical practice.
Researchers have unveiled primary trial results that show encouraging advances in HIV treatment driven by immune-based therapies. New antibody therapies could offer alternative to current treatments.
The Goding lab, working in collaboration with the University Rey Juan Carlos, have shown that fatty acid uptake activates an AXL-CAV1-\u03b2-catenin axis to drive melanoma invasiveness.
A landmark study involving researchers from NDM\u2019s Centre for Human Genetics has identified 69 previously unidentified genetic determinants of rare disease, including uncommon forms of epilepsy and schizophrenia.
The Ineos Oxford Institute for antimicrobial research (IOI) has awarded \u00a35 million to a group of interdisciplinary researchers from NDM and other departments at the University, to develop new therapies for drug-resistant tuberculosis.
After more than a year of community engagement and preparation in 100 villages with over 12,000 inhabitants across the Chittagong Hill Tracts, a mass malaria vaccine (R21/Matrix M) and drug administration (DHA, piperaquine, and single low dose primaquine) study was launched on 15 February.
In the first study of this kind, NDM\u2019s Pandemic Sciences Institute and Oxford researchers partner with global colleagues to outline how artificial intelligence can transform infectious disease research and save more lives.
A team of researchers at OUCRU was recently awarded a multi-million-dollar Discovery Award from the Wellcome Trust to develop AI tools to advance pneumonia research.
A new home test to diagnose type-1 diabetes (T1D) is being investigated in a major UK study led by researchers at the National Institute for Health and Care Research (NIHR) Oxford Biomedical Research Centre and NDM's Centre for Human Genetics.
Researchers in NDM have authored a collaborative study which explored a new method for detecting bowel cancer, which was found to be more than 90% accurate at predicting which higher-risk people will develop this type of cancer in the future.
Researchers in the Nuffield Department of Medicine and their collaborators, including the Serum Institute of India, have published an innovative method to identify falsified vaccines without opening the vaccine vial. The new method analyses the vaccine vial label and its adhesive and therefore allows genuine vaccine vials to be retained in the supply chain. This technique can also differentiate genuine Covid-19 vaccine liquid from falsified vaccine surrogates.
New research from NDM\u2019s Target Discovery Institute, the MRC Laboratory of Molecular Biology and University College London has shed light on a potential pathway for the spread of harmful tau protein in Alzheimer's disease. Their findings, published in Nature Neuroscience, focus on structures called extracellular vesicles and their role in transporting toxic tau fragments.
Results of MOSAIC, a European observational study led by researchers at PSI and ISARIC, provides evidence on how the clade IIb mpox virus affects patients and the risks of onward transmission.
Dr Pablo F. C\u00e9spedes, CAMS Oxford Institute Career Development Fellow, has received funding from NC3Rs to establish a lymphoid organoid and explant hub for researchers across the country.
![\"\"](\"https://www.ndm.ox.ac.uk/news/research-team-receive-ps5-5m-funding-to-transform-bowel-cancer-care/responsive_image?ratio=r16x9&scale=w760\")
\n \n \n\n\n